Gynaecomastia secondary to transdermal oestradiol used for androgen deprivation therapy: informed reality vs subjective fear
BJU International · 2026-11 · 138 (5) · 815-821
DOI: 10.1111/bju.70374 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BJU International, online erschienen am 14.07.2026. Verfasst von Carly Sears und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Gynecomastia, Estradiol, Androgen Antagonists, Prostatic Neoplasms. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Objectives
To provide information that can aid patients with prostate cancer (PCa) and their uro‐oncologists in shared decision‐making discussions about androgen deprivation therapy (ADT), with transdermal oestradiol (tE2) as one option. We do so by summarising recent literature on breast growth in genetic males undergoing treatment with exogenous E2. Based on the amount of breast development observed in this population, we estimate the maximum amount of breast growth that patients with PCa can expect, if they elect tE2 for ADT. We also present data on risks and management of mastalgia associated with tE2.
Methods
We summarise findings from five studies involving a total of 480 trans women (i.e., genetic males) undergoing gender‐affirming hormone treatment with exogenous oestrogen.
Results
Exogenous E2 typically induces less than an A‐cup size among trans women. The majority of breast growth occurs within the first year of treatment. We present this evidence to illustrate that the degree of gynaecomastia patients with PCa can expect if they elect tE2 for ADT is quite modest. This information can allay the often‐heightened concern patients with PCa and their uro‐oncologists may have regarding gynaecomastia induced by tE2 when used for ADT.
Conclusion
Development of breast tissue in genetic males taking exogenous E2 tends to be mild and typically results in less than A‐cup size. Mastalgia in the form of breast and nipple sensitivity is common with E2 treatment in patients with PCa but is transient in most cases, responds to topical anti‐inflammatory agents, and can be managed with neurectomy in severe cases. This information can help clinicians provide accurate counselling and mitigate misconceptions that may dissuade patients from considering tE2 for their ADT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Calgary, Calgary, Alberta, Canada.
- Sandia National Laboratories (Ret.), Albuquerque, New Mexico, USA.
- Simon Fraser University, Vancouver, British Columbia, Canada.
- Macon and Joan Brock Virginia Health Sciences, Eastern Virginia Medical School, Norfolk, Virginia, USA.
- Department of Cellular and Physiological Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Richard Wassersug
Zitieren
APA
Sears, C., Watson, R., Brown, E., Abbas, B., Schellhammer, P., & Wassersug, R. (2026). Gynaecomastia secondary to transdermal oestradiol used for androgen deprivation therapy: informed reality vs subjective fear. BJU International, 138(5), 815-821. https://doi.org/10.1111/bju.70374
Vancouver
Sears C, Watson R, Brown E, Abbas B, Schellhammer P, Wassersug R. Gynaecomastia secondary to transdermal oestradiol used for androgen deprivation therapy: informed reality vs subjective fear. BJU International. 2026;138(5):815-821. doi:10.1111/bju.70374
BibTeX
@article{Sears2026,
author = {Sears, Carly and Watson, Robert and Brown, Eric and Abbas, Badra and Schellhammer, Paul and Wassersug, Richard},
title = {Gynaecomastia secondary to transdermal oestradiol used for androgen deprivation therapy: informed reality vs subjective fear},
journal = {BJU International},
year = {2026},
volume = {138},
number = {5},
pages = {815--821},
doi = {10.1111/bju.70374}
}
EUVIMED